NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-21-082 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program.
Funding Opportunity RFA-HS-21-001 from the NIH Guide for Grants and Contracts. This initiative will fund up to 5 projects to use lessons learned from previous AHRQ primary care practice improvement initiatives to implement and test implementation strategies to address urinary incontinence in women, and to integrate it with specialty care. Projects may draw on community-based resources and/or include multilevel implementation strategies aligning improvement strategies between primary care practices and healthcare systems.
Notice NOT-DA-21-026 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-003 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-148 from the NIH Guide for Grants and Contracts. The purpose of the NIOSH Support for Conferences and Scientific Meetings (R13) is to support high quality scientific meetings, conferences, and workshops that are relevant to NIOSHs scientific mission and that promote occupational safety and health, NIOSH program priorities, and public health. The conference program is integral to the overall mission of NIOSH. An application should address and advance important areas of research in the field of occupational safety and health of particular interest to NIOSH programs and the National Occupational Research Agenda.
Funding Opportunity PA-21-110 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) pre-trial feasibility and acceptability testing of services and service system research relevant to the prevention of substance use. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through FOA include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.
Funding Opportunity RFA-TR-21-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease. To facilitate clinical trial start up, and leverage existing datasets, preference will be given to applications focusing on diseases that are under study by the Rare Disease Clinical Research Network (RDCRN), and that involve collaborations with RDCRN clinical investigators.
Funding Opportunity RFA-DK-21-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinicaltrials and patient care. This initiative would support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative would leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples. The goal of this initiative is to deliver candidate biomarkers that are ready for definitive analytical and clinical validation studies through the Diabetic Foot Consortium.
Notice NOT-HS-21-007 from the NIH Guide for Grants and Contracts
Notice NOT-RM-21-010 from the NIH Guide for Grants and Contracts
Notice NOT-MH-21-155 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-20-078 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or non-pathogenic microbes or vaccination against infectious diseases, allergens, and environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.
Funding Opportunity RFA-AI-20-077 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or non-pathogenic microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.
Funding Opportunity PAR-21-062 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.
Notice NOT-GM-21-015 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-002 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-21-030 from the NIH Guide for Grants and Contracts. enter purposeChronic Non-Cancer Pain (CP) and Opioid Use Disorder (OUD) overlap significantly and patients with both conditions present particular clinical complexity. CP adversely impacts OUD treatment adherence and recovery, while the presence of dependence stigmatizes treatment services for chronic pain, often resulting in insufficient pain treatment. Fundamentally, the healthcare system lacks the expertise and effective interventions for managing comorbid CP and OUD, leaving patients suffering and at risk for poor outcomes. The National Institutes of Health (NIH) intends to establish a national network consisting of investigators conducting Collaborative research on Co-managing Chronic Pain and Opioid Use Disorder (C3PO), which will be supported by a Resource on Related DSM-5 Diagnoses (R2D2) Coordination and Dissemination center. This network is intended to facilitate multidisciplinary team science collaborations that can create actionable, translatable, and sustainable treatments to improve the capacity of the health care system to effectively respond to the opioid epidemic. The network will be part of the NIHs Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management.
Funding Opportunity RFA-DA-21-029 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) intends to establish a Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) network consisting of clinical research centers, which will be supported by a single Coordination and Dissemination center. This network is intended to create multidisciplinary team science collaborations to develop effective interventions, best models of care for delivery of services, and sustainable implementation strategies for access to quality care for complex patients with chronic pain (CP) and opioid use disorder (OUD) or opioid misuse. The network will be part of the NIHs Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management.
Funding Opportunity PAR-21-109 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to provide tailored support for early stage investigators (ESIs) to initiate basic or translational research with nonhuman primates (NHPs). These awards will allow ESIs additional funds, time to generate preliminary data, and the opportunity to establish all skills needed to set up and run an NHP laboratory independently. It is expected that these awards will thereby improve an ESIs ability to secure larger research awards (e.g., R01) and will facilitate their transition to independent tenure-track positions.
Funding Opportunity RFA-MH-21-145 from the NIH Guide for Grants and Contracts. As part of NIHs Helping to End Addiction Long Term (HEAL) Initiative, this RFA invites research that will optimize multi-component service delivery interventions for people with opioid use disorder and co-occurring conditions, to include suicide risk. The purpose of the initiative is to support studies that will test (1) overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions. Studies are to be highly pragmatic and practice relevant, with designs that balance rigor with time-to-practice urgency. Projects will seek to a) identify constitute components that drive improvements in access, continuity, quality, value, and outcomes of care, for service delivery interventions with previously demonstrated effectiveness as a bundled package; and b) simultaneously test overall effectiveness of the package and its subcomponents, for popular (widely implemented) service delivery packages without previously demonstrated effectiveness.